

## MDS Hub | Quarter One 2021 Update

Wednesday 7 April, 2021

The MDS Hub provides updated and balanced information on clinical management, state-of-the-art research, and therapeutic development in myelodysplastic syndromes (MDS). It is a platform where healthcare professionals can easily keep up to date with the latest breakthroughs in the field without any hassle or cost.

The MDS Hub is constituted in partnership with the European LeukemiaNet and Scientific Education Support. We are grateful to our supporters Novartis (Silver) and BMS (Bronze), and this quarter, we were Related delighted to welcome our new supporters, Geron Corporation (Contributor), and Takeda (Contributor).

In the first Steering Committee meeting after the MDS Hub launch, we reviewed the unmet educational needs and discussed how to deliver interesting and helpful information to the community. The invaluable input provided by our expert panel will guide the activities and content covered on the MDS Hub throughout the year. Meet all the members here!

During the first quarter of 2021, advances and new perspectives in the treatment of MDS were shared from distinguished experts in hematology at the 7th Translational Research E-Conference: Myelodysplastic Syndromes organized by the European School of Haematology (ESH). During our live coverage, we shared the current challenges and new data on MDS pathophysiology, diagnosis, and

In early March, we provided coverage for the ESH 2nd Translational Research E-Conference: Erythropoiesis Control and Ineffective Erythropoiesis, led by outstanding faculty of global experts in hematology. Featured interviews on the impact of SARS CoV-2 infection on hematopoiesis, innovations for anemia treatment, and promising immunotherapy approaches such as CAR T-cell therapy for MDS, are available on our website.

Later in March, virtual coverage of the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) allowed us to obtain the opinion of experts on the latest research and innovation in cellular stem cell-based therapies to cure blood-related disorders. Visit our social media channel to revisit some of the most exciting communications, and stay tuned for new articles covering the congress highlights.

For more information on the MDS Hub, please visit our website. For media inquiries or to explore collaboration opportunities, please contact <a href="mailto:secretariat@scientificeducationsupport.com">secretariat@scientificeducationsupport.com</a>.

Media:

Related Sectors:

Media & Marketing :: Medical & Pharmaceutical:

# **Keywords:**

MDS :: Myelodysplastic Syndromes :: Cancer :: Hematology ::

### Scan Me:



**Distributed By Pressat** 



## **Company Contact:**

## **Scientific Education Support**

E. <u>Abbie.Gunn@scientificeducationsupport...</u>
W. <u>https://www.scientificeducationsuppor...</u>

### View Online

Additional Assets: https://mds-hub.com/

**Newsroom:** Visit our Newsroom for all the latest stories: <a href="https://www.scientific-education-support.pressat.co.uk">https://www.scientific-education-support.pressat.co.uk</a>

<u>Distributed By Pressat</u> page 2 / 2